To determine cell surface expression of CD36, cells were labelled with anti-human CD36 antibody (FA6-152, Stem Cell Technologies, Vancouver, Canada) or isotype control (IgG 1 κ) at a concentration of 10 µg/ml in
RPMI1640 media (Sigma-Aldrich, Merck, Sydney Australia) containing 10% FBS. Cells were then washed and stained with a secondary antibody,
goat anti-mouse IgG H&L Dylight 650 (Clone ab96882, Abcam, Cambridge, United Kingdom) at a concentration of 5 µg/ml. Cell viability was determined via
7AAD (BD Biosciences) staining at a 1:20 dilution. Samples were processed using a
BD Accuri C6 ow cytometer (BD, Becton, Dickinson and Company, New Jersey, USA) and data analyzed using
FCS Express 4 Flow Research Edition (De Novo software, Los Angeles, USA).
CD36 knockdown using siRNA CD36 targeting small interfering RNAs (siRNAs)
Trilencer-27 Human siRNA duplexes at 20µM were purchased (Origene, Maryland, USA) with three CD36 targeting siRNAs (A, B and C) plus a non-targeting scrambled (SCR) siRNA used as a negative control. Transfection was performed using
Lipofectamine RNAiMAX (Invitrogen by Life Technologies, California, USA) as per the manufacturer's instructions with the knockdown maximized at 5nM and validated by ow cytometry.
Martini C., DeNichilo M., King D.P., Cockshell M.P., Ebert B., Dale B., Ebert L.M., Woods A.E., & Bonder C.S. (2021). CD36 Promotes Vasculogenic Mimicry in Melanoma by Mediating Adhesion to the Extracellular Matrix.